Shareholders' Equity (Details)
|
|
|
|
1 Months Ended |
6 Months Ended |
9 Months Ended |
|
Aug. 03, 2017
USD ($)
$ / shares
|
Sep. 04, 2015
Employees
Director
shares
|
Jun. 01, 2015
shares
|
Apr. 24, 2017
shares
|
May 31, 2016
shares
|
Apr. 30, 2016
shares
|
Jun. 30, 2017
USD ($)
|
Sep. 30, 2017
USD ($)
shares
|
Sep. 30, 2016
USD ($)
shares
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Stock based compensation |
|
|
|
|
|
|
|
$ 4,829,598
|
$ 4,866,324
|
| Gross proceeds from equity |
$ 7,000,000
|
|
|
|
|
|
|
|
|
| Stock award agreements [Member] |
|
|
|
|
|
|
|
|
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Shares of restricted common stock issued | shares |
|
450,000
|
|
|
|
|
|
|
|
| Stock based compensation |
|
|
|
|
|
|
|
|
604,440
|
| Recognized total expense |
|
|
|
|
|
|
|
|
60,495
|
| Number of management employees | Employees |
|
4
|
|
|
|
|
|
|
|
| Number of director | Director |
|
1
|
|
|
|
|
|
|
|
| Chairman of the Board [Member] |
|
|
|
|
|
|
|
|
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Shares of restricted common stock issued | shares |
|
|
50,000
|
|
|
|
|
|
|
| Recognized total expense |
|
|
|
|
|
|
|
112,500
|
202,500
|
| Vesting period term |
|
|
24 months
|
|
|
|
|
|
|
| Dr. Philip Frost and Steven Rubin [Member] |
|
|
|
|
|
|
|
|
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Common stock issued, shares | shares |
|
|
|
|
150,000
|
|
|
|
|
| Recognized total expense |
|
|
|
|
|
|
|
$ 29,500
|
211,890
|
| Vesting period term |
|
|
|
|
12 months
|
|
|
|
|
| 2015 Equity Plan [Member] |
|
|
|
|
|
|
|
|
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Shares of restricted common stock issued | shares |
|
|
|
|
|
|
|
5,210,000
|
|
| Shares vest upon consummation of equity and/or debt financing |
|
|
|
|
|
|
|
|
5,000,000
|
| Stock based compensation |
|
|
|
|
|
|
$ 970,067
|
$ 1,488,596
|
28,808
|
| 2015 Equity Plan [Member] | Stock award agreements [Member] |
|
|
|
|
|
|
|
|
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Shares of restricted common stock issued | shares |
|
|
|
|
|
1,150,000
|
|
|
|
| Stock based compensation |
|
|
|
|
|
|
|
|
$ 3,346,615
|
| Common stock issued, shares | shares |
|
|
|
|
|
|
|
|
100,000
|
| SAB Amendments [Member] |
|
|
|
|
|
|
|
|
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Recognized total expense |
|
|
|
|
|
|
|
$ 104,167
|
|
| Restricted common stock, description |
The SAB Amendments extend the term of the agreements from May 1, 2017 until April 30, 2018 and provide for the following equity based compensation: (a) for Dr. Frost, a warrant to purchase 2,000,000 shares of the Company's Common Stock (the "Frost Warrant") and an award of 150,000 shares of the Company's unregistered restricted Common Stock and (b) for Mr. Rubin, an award of 100,000 shares of the Company's unregistered restricted Common Stock. The restricted stock vests upon the occurrence of a change of control (as defined in the SAB Amendments).
|
|
|
|
|
|
|
|
|
| Warrant Term |
5 years
|
|
|
|
|
|
|
|
|
| Warrant exercise price | $ / shares |
$ 1.00
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
| Shareholders' Equity (Textual) |
|
|
|
|
|
|
|
|
|
| Preferred stock converted shares | shares |
|
|
|
100,100
|
|
|
|
|
|
| Aggregate shares of restricted common stock | shares |
|
|
|
250,250
|
|
|
|
|
|